EstroGel (estradiol) / AbbVie, Besins Healthcare - LARVOL DELTA

Oestrogel HRT regimens prescribed in General Practice. (PubMed, Ulster Med J) - No abstract available

Journal

In Vitro Percutaneous Absorption of Permeation-Enhancing Estrogen Formulations. (PubMed, Pharmaceuticals (Basel)) - "The objective of this in vitro study is to evaluate the percutaneous absorption of compounded estradiol 0.06% and bi-est E3/E2 0.1%/0.06% in aqueous and anhydrous proprietary permeation-enhancing bases, in comparison with the commercially available estradiol transdermal gel (ESTROGel®). The compounded bases facilitated a steady percutaneous absorption of estradiol, without quick peaking or declining, which is one of the desired characteristics in HRT. Compounding pharmacists and practitioners may consider estradiol compounded formulations as a viable option for hormone delivery to patients."

Journal • Preclinical

Changes in menopause-specific quality of life between women with transdermal estradiol versus oral estrogens: results of a randomized controlled trial. (PubMed, Gynecol Endocrinol) - "257 women aged 40-55 years, within three years after their final menstrual period were randomized to receive transdermal oestrogel (t-E2) (n = 128) or oral estradiol valerate (o- E2V) (n = 129; both with micronized progesterone 200 mg for 14 days each month). The decrease of MENQOL scores after treatment showed almost no difference between the two groups (p > 0.05) except the VMS domain which indicated a better result in oral estrogen group after 24 weeks. This study showed that both transdermal and oral estrogens were highly effective in relieving the overall menopausal symptoms for recently-menopausal women, with little difference in treatment efficacy between the two routes."

Clinical • HEOR • Journal

DECLARED-CT: Effects of Menopausal Hormone and GLP-1 Agonist Therapy on Glucose and Energy Homeostasis in Postmenopausal Women (clinicaltrials.gov) - P=N/A | N=96 | Not yet recruiting | Sponsor: Lia Bally

New trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Estrogen Hormone Products (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: Oct 2024 ➔ Mar 2025 | Trial primary completion date: Oct 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date

How to Tailor Transdermal Menopausal Hormone Therapy (MHT) to our Patients with a Clinically Meaningful Effect (ISGE 2024) - "2.5 g dosage of Estrogel® applied daily was the most effective dose of gel comparable with Climara® patch and 1 and 2 mg E2 oral tablet efficacy. Lower dosages did not appear to adequately relieve symptoms or there was a lag before effects were observed, independently of the route of administration."

Clinical • Pain

Estrogen Hormone Products (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: University of Maryland, Baltimore | Not yet recruiting ➔ Recruiting

Enrollment open

Drugs for menopausal symptoms. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Estrogen Hormone Products (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: University of Maryland, Baltimore | Initiation date: Oct 2023 ➔ Jan 2024

Trial initiation date

Estrogen Hormone Products (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: Aug 2023 ➔ Aug 2024 | Initiation date: Apr 2023 ➔ Aug 2023 | Trial primary completion date: Aug 2023 ➔ Aug 2024

Trial completion date • Trial initiation date • Trial primary completion date

In vitro percutaneous absorption of extemporaneously compounded estradiol formulations (ISID 2023) - "The commercial medication ESTROGel (estradiol 0.06%) was used as positive control...It is demonstrated that estradiol penetrates through the skin upon topical application of aqueous and anhydrous compounded formulations. These results are important evidence to support the effectiveness of cHRT since the in vitro model used has proven to accurately predict in vivo permeation kinetics."

Preclinical

Estrogen Hormone Products (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: University of Maryland, Baltimore | Initiation date: Jan 2023 ➔ Apr 2023

Trial initiation date

Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women. (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Viramal Limited | Trial completion date: Dec 2021 ➔ Apr 2022 | Trial primary completion date: Oct 2021 ➔ Apr 2022

Trial completion date • Trial primary completion date

Management of asymptomatic hypoglycemia with 40% oral dextrose gel in near term at-risk infants to reduce intensive care need and promote breastfeeding. (PubMed, Ital J Pediatr) - "In our population of near term infants, the introduction of 40% oral dextrose gel to the protocol, helped in the safe management of asymptomatic hypoglycemia and, at the same time, implemented breastfeeding."

Journal • Critical care • Hypoglycemia

Oestrogen Treatment for COVID-19 Symptoms (clinicaltrials.gov) - P2; N=2000; Not yet recruiting; Sponsor: Hamad Medical Corporation

New P2 trial • Infectious Disease • Novel Coronavirus Disease

Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women. (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Viramal Limited; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Oct 2020 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date

A comparison of the effects of three different estrogen used for endometrium preparation on the outcome of day 5 frozen embryo transfer cycle. (PubMed, JBRA Assist Reprod) - "In FET cycles with oral (Primogyna) or transdermal patches (Estradot), or transdermal gel (Oestrogel Pump), there was no significant difference on pregnancy rates."

Journal

Drugs for menopausal symptoms. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol. (PubMed, JBRA Assist Reprod) - "No significant differences were seen in the pregnancy rates of patients submitted to IVF-ET cycles with GnRH antagonists given oral, transdermal patches, or transdermal gel E2 during the luteal phase. A correlation was found between clinical pregnancy rate and AMH and E2 levels on beta hCG testing day."

Journal • Gynecology

Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women. (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Viramal Limited; Trial completion date: Apr 2020 ➔ Dec 2020; Trial primary completion date: Mar 2020 ➔ Oct 2020

Clinical • Trial completion date • Trial primary completion date

Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women. (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Viramal Limited; Trial completion date: Jan 2020 ➔ Apr 2020; Trial primary completion date: Dec 2019 ➔ Mar 2020

Clinical • Trial completion date • Trial primary completion date

Prevention of Hypoglycaemia by Oral 40% Destrogel (clinicaltrials.gov) - P=N/A; N=172; Completed; Sponsor: Fondazione Poliambulanza Istituto Ospedaliero

New trial

Estradiol/progesterone (Bijuva) for menopausal vasomotor symptoms. (PubMed, Med Lett Drugs Ther) - No abstract available.

Journal

Colorectal cancer screening. (PubMed, Med Lett Drugs Ther) - No abstract available.

Journal

Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women. (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Viramal Limited; Trial primary completion date: Jul 2019 ➔ Oct 2019

Trial primary completion date